Level D· Scientific groundwork from lab and animal studiesNarrative ReviewPubMed

Integrated strategies from stem cells to exosomes for amelioration of insulin resistance and promoting β-cell regeneration in diabesity.

Singh H., Bhaskar R., Ghosh S., Mishra PK., Singh KK., Sinha JK.

Narrative Review on Type 2 Diabetes, Chronic Inflammation, published in Tissue Cell (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Tissue Cell (2025)
Country
Scotland
Reported sample size
—
Source database
PubMed
PMID
41455419
DOI
10.1016/j.tice.2025.103293

Abstract (original English)

The simultaneous epidemic of obesity and type 2 diabetes is driven by insulin resistance, chronic inflammation, and progressive β-cell dysfunction within an obese, lipotoxic microenvironment. Conventional therapies may improve glycemic control but rarely reverse the underlying metabolic damage or restore long-term homeostasis. Regenerative strategies based on stem cells such as mesenchymal stem cells (MSCs), adipose-derived stem cells (ASCs), and induced pluripotent stem cells (iPSCs), together with their extracellular vesicles (EVs) and exosomes have emerged as promising approaches to address both β-cell failure and obesity-related pathology. These interventions may restore β-cell mass and function, enhance insulin sensitivity, and remodel dysfunctional adipose tissue through direct cell replacement and paracrine signaling. This review emphasizes integrated strategies that combine stem cells, exosomes, pharmacological agents, and tissue-engineering platforms (3-D scaffolds, hydrogels, and exosome delivery systems) to achieve synergistic and more durable metabolic benefits in diabesity. Particular focus is placed on how these combinations address adipose tissue inflammation and fibrosis, ectopic lipid accumulation, brown/beige adipose tissue dysfunction, and enhance glycemic control indices. Although preclinical and early-phase clinical studies are encouraging, major challenges

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
HumansExosomesInsulin ResistanceInsulin-Secreting CellsRegenerationAnimalsDiabetes Mellitus, Type 2Stem CellsDiabesity

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research